Monoaminergic involvement in the behavioral effects of ergot derivatives.

J. B. Appel, Kathryn Cunningham, K. B. West

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Monoaminergic neuronal systems have been implicated in the mechanisms of action of most ergot derivatives (including those that are clinically useful and those that are "hallucinogenic"). Among the various assays that have been useful in determining the extent of such involvement is drug discrimination. In this procedure, animals are trained to respond in one way (e.g., press the right lever) following saline and to respond differently (e.g., press the left lever) after either a particular ergot or a neurotransmitter agonist, and are subsequently tested with other ergots, transmitter agonists or antagonists (alone or in combination with the training drug). The results to date indicate that: 1) There are similarities in the discriminable effects of lergotrile, lisuride and bromocriptine, which probably involve catecholaminergic neuronal systems (DA or NE). 2) These effects are clearly separable from those of ergonovine and LSD, which may be relatively more serotonergic. More precise delineation of the mechanisms underlying these cues (e.g., D1, D2-selective agonism, antagonism, etc.) awaits further testing with highly specific pharmacological interventions.

Original languageEnglish (US)
Pages (from-to)51-62
Number of pages12
JournalProgress in Clinical and Biological Research
Volume192
StatePublished - 1985
Externally publishedYes

Fingerprint

Lisuride
Ergonovine
Lysergic Acid Diethylamide
Bromocriptine
Pharmaceutical Preparations
Cues
Neurotransmitter Agents
Pharmacology
Discrimination (Psychology)
lergotrile

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monoaminergic involvement in the behavioral effects of ergot derivatives. / Appel, J. B.; Cunningham, Kathryn; West, K. B.

In: Progress in Clinical and Biological Research, Vol. 192, 1985, p. 51-62.

Research output: Contribution to journalArticle

@article{0ca52839f355409dbce9b543f7d78272,
title = "Monoaminergic involvement in the behavioral effects of ergot derivatives.",
abstract = "Monoaminergic neuronal systems have been implicated in the mechanisms of action of most ergot derivatives (including those that are clinically useful and those that are {"}hallucinogenic{"}). Among the various assays that have been useful in determining the extent of such involvement is drug discrimination. In this procedure, animals are trained to respond in one way (e.g., press the right lever) following saline and to respond differently (e.g., press the left lever) after either a particular ergot or a neurotransmitter agonist, and are subsequently tested with other ergots, transmitter agonists or antagonists (alone or in combination with the training drug). The results to date indicate that: 1) There are similarities in the discriminable effects of lergotrile, lisuride and bromocriptine, which probably involve catecholaminergic neuronal systems (DA or NE). 2) These effects are clearly separable from those of ergonovine and LSD, which may be relatively more serotonergic. More precise delineation of the mechanisms underlying these cues (e.g., D1, D2-selective agonism, antagonism, etc.) awaits further testing with highly specific pharmacological interventions.",
author = "Appel, {J. B.} and Kathryn Cunningham and West, {K. B.}",
year = "1985",
language = "English (US)",
volume = "192",
pages = "51--62",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Monoaminergic involvement in the behavioral effects of ergot derivatives.

AU - Appel, J. B.

AU - Cunningham, Kathryn

AU - West, K. B.

PY - 1985

Y1 - 1985

N2 - Monoaminergic neuronal systems have been implicated in the mechanisms of action of most ergot derivatives (including those that are clinically useful and those that are "hallucinogenic"). Among the various assays that have been useful in determining the extent of such involvement is drug discrimination. In this procedure, animals are trained to respond in one way (e.g., press the right lever) following saline and to respond differently (e.g., press the left lever) after either a particular ergot or a neurotransmitter agonist, and are subsequently tested with other ergots, transmitter agonists or antagonists (alone or in combination with the training drug). The results to date indicate that: 1) There are similarities in the discriminable effects of lergotrile, lisuride and bromocriptine, which probably involve catecholaminergic neuronal systems (DA or NE). 2) These effects are clearly separable from those of ergonovine and LSD, which may be relatively more serotonergic. More precise delineation of the mechanisms underlying these cues (e.g., D1, D2-selective agonism, antagonism, etc.) awaits further testing with highly specific pharmacological interventions.

AB - Monoaminergic neuronal systems have been implicated in the mechanisms of action of most ergot derivatives (including those that are clinically useful and those that are "hallucinogenic"). Among the various assays that have been useful in determining the extent of such involvement is drug discrimination. In this procedure, animals are trained to respond in one way (e.g., press the right lever) following saline and to respond differently (e.g., press the left lever) after either a particular ergot or a neurotransmitter agonist, and are subsequently tested with other ergots, transmitter agonists or antagonists (alone or in combination with the training drug). The results to date indicate that: 1) There are similarities in the discriminable effects of lergotrile, lisuride and bromocriptine, which probably involve catecholaminergic neuronal systems (DA or NE). 2) These effects are clearly separable from those of ergonovine and LSD, which may be relatively more serotonergic. More precise delineation of the mechanisms underlying these cues (e.g., D1, D2-selective agonism, antagonism, etc.) awaits further testing with highly specific pharmacological interventions.

UR - http://www.scopus.com/inward/record.url?scp=0022293657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022293657&partnerID=8YFLogxK

M3 - Article

C2 - 2867556

AN - SCOPUS:0022293657

VL - 192

SP - 51

EP - 62

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -